Novartis AG (NYSE:NVS) – Research analysts at Leerink Swann issued their FY2022 earnings per share (EPS) estimates for Novartis in a research note issued on Wednesday. Leerink Swann analyst S. Fernandez expects that the company will post earnings of $7.11 per share for the year. Leerink Swann has a “Market Perform” rating and a $91.00 price objective on the stock.
Novartis (NYSE:NVS) last released its quarterly earnings results on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.04. The business had revenue of $12.92 billion during the quarter, compared to analyst estimates of $12.65 billion. Novartis had a net margin of 15.69% and a return on equity of 16.03%. The company’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.14 earnings per share.
Shares of Novartis (NVS) opened at $93.91 on Monday. The company has a market cap of $245,960.00, a PE ratio of 28.90, a price-to-earnings-growth ratio of 2.20 and a beta of 0.74. Novartis has a 1 year low of $71.50 and a 1 year high of $94.19. The company has a current ratio of 1.21, a quick ratio of 0.91 and a debt-to-equity ratio of 0.31.
Several institutional investors have recently made changes to their positions in NVS. Welch & Forbes LLC increased its holdings in Novartis by 0.8% in the 4th quarter. Welch & Forbes LLC now owns 110,312 shares of the company’s stock worth $9,263,000 after buying an additional 872 shares during the period. Advisor Partners LLC increased its holdings in Novartis by 55.5% in the 4th quarter. Advisor Partners LLC now owns 7,855 shares of the company’s stock worth $683,000 after buying an additional 2,802 shares during the period. Moloney Securities Asset Management LLC increased its holdings in Novartis by 58.7% in the 4th quarter. Moloney Securities Asset Management LLC now owns 4,564 shares of the company’s stock worth $383,000 after buying an additional 1,688 shares during the period. Garland Capital Management Inc. grew its stake in shares of Novartis by 1.0% during the 4th quarter. Garland Capital Management Inc. now owns 52,233 shares of the company’s stock worth $4,385,000 after purchasing an additional 535 shares during the period. Finally, FTB Advisors Inc. grew its stake in shares of Novartis by 4.8% during the 4th quarter. FTB Advisors Inc. now owns 34,613 shares of the company’s stock worth $2,944,000 after purchasing an additional 1,591 shares during the period. 10.86% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Leerink Swann Comments on Novartis AG’s FY2022 Earnings (NVS)” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/29/leerink-swann-comments-on-novartis-ags-fy2022-earnings-nvs.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.